Aciex Therapeutics has entered into a collaborative research agreement with Portola Pharmaceuticals that provides Aciex with exclusive rights to develop Portola’s small molecule dual Spleen Tyrosine Kinase (Syk)/Janus Kinase (JAK) inhibitors for ophthalmic indications. Portola’s library includes compounds with preclinical systemic data packages as well as earlier stage research compounds. The two companies will develop the drugs to treat topical ophthalmic diseases, including ocular allergy, dry eye and other inflammatory eye conditions.
Aciex will have access to Portola’s small molecule dual Syk/JAK inhibitors and will lead clinical development activities for ophthalmic indications. Both companies will fund and participate in development activities. Portola retains the right to develop these compounds for non-ophthalmic indications. Financial terms were not disclosed.
“This strategic partnership combines Aciex’s specific ophthalmic research and development capability with Portola’s expertise in cellular signaling pathways and medicinal chemistry to advance treatments for inflammatory ocular conditions,” said Les Kaplan, Ph.D., executive chairman of Aciex. “Aciex shares with Portola a common goal of using leading-edge science to develop and deliver therapies for patients who currently have limited or no approved treatments.”